Latest news with #DaleLevitzke
Yahoo
09-04-2025
- Business
- Yahoo
Sphere Bio Expands APAC Distribution Network to Strengthen Presence in Region
Operational scale-up accelerates global growth strategy to increase regional access and technical support CAMBRIDGE, England, April 09, 2025--(BUSINESS WIRE)--Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company's global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms. The expansion enhances Sphere Bio's footprint across key Asian and Pacific markets, improving regional access to its innovative technologies, local support, and technical expertise. The Company has formed partnerships with five new distributors: 1st PhileKorea (South Korea), AS ONE Corporation (Japan), Decode Science (Australia and New Zealand), Everlife Research Instruments (Singapore), and Premas Life Sciences (India and Bangladesh). These new partnerships join an already robust network, including Bang Trading (Thailand), Cold Spring Biotech (Taiwan), and Gene Company (China and Hong Kong). This strategic scale-up enhances Sphere Bio's ability to provide localized product support and increase adoption of its growing technology portfolio, including the recently launched Cyto-Mine® Chroma platform and new assay offerings. The investment in new partnerships reflects the Company's long-term commitment to serving the region and supporting local customers with in-depth expertise. Dale Levitzke, CEO, Sphere Bio, commented: "2025 is a pivotal year as we scale to meet growing global demand and enter high-growth markets. We have partnered with best-in-class distributors to extend our reach and bring our transformative solutions to more customers worldwide. This expansion supports our mission to accelerate scientific discovery through innovation in single-cell analysis." Jay Manikandan, VP Commercial (APAC), Sphere Bio, added: "Our expanded distributor network and enhanced presence reflects our commitment to providing localized customer and technical support across the APAC region. These developments represent an important step in bringing our solutions closer to researchers and advancing global adoption." To learn more about Sphere Bio's integrated life sciences tools and solutions, please visit View source version on Contacts For further information please contact: Dr Claire CoxSphere Bio +44 (0)7365 209 441Email: Zyme Communications Lily JefferyTel: +44 (0)7891 477 378Email: Sign in to access your portfolio
Associated Press
27-01-2025
- Business
- Associated Press
Sphere Fluidics Launches Cyto-Mine Chroma and Announces Early Access Program
CAMBRIDGE, England--(BUSINESS WIRE)--Jan 27, 2025-- Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine ® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego. Cyto-Mine Chroma represents the next generation of Sphere Fluidics' industry-leading Cyto-Mine single-cell analysis platform. The Early Access Program provides an opportunity to be among the first to demo the Cyto-Mine Chroma for faster project timeline completion and improved outcomes across broad applications, including antibody discovery, cell line development, and emerging areas such as cell therapy. Through the program, the Company will collaborate closely with forward-thinking customers to drive innovation and inform the development of future applications and assays on the platform. Offering enhanced capabilities, including multiplexing and greater assay flexibility, Cyto-Mine Chroma has been developed to maximize the efficiency and precision of single-cell functional analysis – enabling tens of millions of cells to be screened in a day. Leveraging a four-color laser and detector system, Cyto-Mine Chroma expands the number of parameters that can be analyzed for each cell in a single assay. This supports the upcoming launch of the Company's first multiplexed assay kit, facilitating multiple readouts within a single experiment, optimizing the throughput and precision of cell selection. By accelerating the early selection of superior candidate cells for downstream expansion or further analysis, overall timelines are reduced from months to weeks, while reducing effort and cost. Sphere Fluidics will be showcasing Cyto-Mine Chroma at its booth (#2744) at SLAS2025. Chief Technology Officer, Richard Hammond, will be presenting a Solutions Spotlight demonstrating the new platform's capabilities on day two of the conference, Tuesday January 28 th, 12:00 – 12:20pm. 'The next-generation Cyto-Mine Chroma platform has been designed to transform single-cell analysis. We are excited to unveil this innovative platform and its Early Access Program at SLAS, the premier event for lab automation and screening. This launch underscores our dedication to advancing biotechnology. Collaborating closely with key industry stakeholders and researchers will allow us to ensure our microfluidic technologies meet the evolving needs of the sector, both now and in the future.' commented Dale Levitzke, CEO, Sphere Fluidics. CONTACT: For further information please contact: Dr Claire Cox Sphere Fluidics Ltd. Tel: +44 (0)7365 209 441 Zyme Communications Lily Jeffery KEYWORD: UNITED KINGDOM EUROPE SOURCE: Sphere Fluidics Copyright Business Wire 2025. PUB: 01/27/2025 04:22 AM/DISC: 01/27/2025 04:22 AM
